Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Therapeutic Advances in Medical OncologyOpen Access

Time to progression is a simple and robust prognostic factor for survival in relapsed or refractory diffuse large B-cell lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

CCChieh‐Lung ChengTHTai‐Chung HuangJLJun Liang

Discussion

Loading...

Member takes

Overview

Retrospective cohort analysis shows time to progression predicts survival in relapsed DLBCL, indicating urgent need for novel therapies.

Key Points

  • To examine the role of time to progression as a prognostic factor in relapsed or refractory diffuse large B-cell lymphoma.
  • Retrospective cohort study of 665 patients treated with R-CHOP.
  • Analysis of clinical data through Cox proportional hazards regression.
  • External validation using a population-based cohort from Taiwan’s National Health Insurance Research Database.
  • 231 patients identified from the retrospective cohort.
  • 2-year overall survival was 35.4% for TTP <12 months and 74.4% for TTP ≥24 months.
  • TTP identified as an independent prognostic factor for overall survival and progression-free survival.

Cite This Study

Cheng et al. (2025) studied this question.

synapsesocial.com/papers/693624ba4fa91c937236c90chttps://doi.org/10.1177/17588359251396884
View Full Paper
Ask AI
Bookmark
Share